Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer Therapies02:49

Cancer Therapies

8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Cancer Therapies02:49

Cancer Therapies

2.4K
2.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the variations in penile cancer care: identifying knowledge gaps and research priorities.

BMJ oncology·2026
Same author

Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Prognostic Factors in Oropharyngeal Cancer Treated With Definitive Chemoradiotherapy.

Cancer medicine·2026
Same author

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic NSCLC.

Ecancermedicalscience·2026
Same author

Contemporary management of adrenocortical carcinoma: A narrative review.

Urologic oncology·2026
Same author

Idiopathic Bell's Palsy in a Patient With Metastatic Lung Adenocarcinoma Receiving Nab-Paclitaxel and Pregabalin: A Rare Clinical Observation.

Case reports in oncological medicine·2026
Same journal

Corrigendum: Long-Term Outcomes of Thymoma Treated at a Single Institute.

South Asian journal of cancer·2026
Same journal

Spindle Cell Variant of Rhabdomyosarcoma: An Aggressive Clinical Case of the Oral Cavity.

South Asian journal of cancer·2025
Same journal

Safety and Efficacy of Alectinib in the First Line for ALK-Mutated Lung Cancer: A Real-World Data from India.

South Asian journal of cancer·2025
Same journal

Retrospective Outcome Analysis of Allogenic Bone Graft.

South Asian journal of cancer·2025
Same journal

Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, India.

South Asian journal of cancer·2025
Same journal

Comparative Analysis of Surgical Site Infections in Pediatric Brain Tumor Patients: Hygiene Practices, Risk Factors, and Implications for Healthcare Costs and Mortality.

South Asian journal of cancer·2025
See all related articles

Related Experiment Video

Updated: May 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Crizotinib: A comprehensive review.

Arvind Sahu1, Kumar Prabhash1, Vanita Noronha1

  • 1Department of Medical Oncology, Tata Memorial Hospital, Ernest Borges Road, Parel, Mumbai, India.

South Asian Journal of Cancer
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

Anaplastic lymphoma kinase (ALK) gene rearrangements identify non-small cell lung cancer patients who benefit from crizotinib treatment. This review covers crizotinib

Keywords:
ALK inhibitorsALK mutationALK positive Non-small cell lung cancerCrizotinib

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Related Experiment Videos

Last Updated: May 3, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Anaplastic lymphoma kinase (ALK) gene rearrangements occur in a subset of non-small-cell lung cancers (NSCLC).
  • ALK rearrangements predict sensitivity to targeted therapies like crizotinib.
  • Effective screening for ALK-positive NSCLC is crucial for treatment integration.

Purpose of the Study:

  • To review the history, mechanism of action, and clinical applications of crizotinib in ALK-positive NSCLC.
  • To discuss adverse effects, dose modifications, and emerging resistance patterns.
  • To explore future challenges and opportunities for ALK-positive lung cancer patients.

Main Methods:

  • Literature review of Phase I and II studies on crizotinib.
  • Analysis of clinical trial data regarding efficacy and safety.
  • Examination of resistance mechanisms and management strategies.

Main Results:

  • Crizotinib demonstrated significant activity and clinical benefit in ALK-positive NSCLC, leading to FDA approval in 2011.
  • The drug induces remissions and extends survival in treated patients.
  • Emerging resistance to crizotinib therapy has been reported.

Conclusions:

  • Crizotinib is an effective targeted therapy for ALK-positive NSCLC.
  • Ongoing research is necessary to overcome resistance and optimize treatment strategies.
  • Development of screening systems is vital for personalized NSCLC treatment.